Embecta Corp. (EMBC)
6.45
+0.27
(+4.37%)
USD |
NASDAQ |
Oct 15, 16:00
6.31
-0.14
(-2.17%)
After-Hours: 07:31
Embecta Research and Development Expense (Quarterly) : 5.60M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.60M |
| March 31, 2026 | 5.40M |
| December 31, 2025 | 0.30M |
| September 30, 2025 | 4.60M |
| June 30, 2025 | 3.80M |
| March 31, 2025 | 3.70M |
| December 31, 2024 | 9.50M |
| September 30, 2024 | 19.80M |
| June 30, 2024 | 20.40M |
| March 31, 2024 | 18.40M |
| December 31, 2023 | 20.20M |
| Date | Value |
|---|---|
| September 30, 2023 | 23.60M |
| June 30, 2023 | 22.60M |
| March 31, 2023 | 22.10M |
| December 31, 2022 | 16.90M |
| September 30, 2022 | 17.00M |
| June 30, 2022 | 14.30M |
| March 31, 2022 | 18.00M |
| December 31, 2021 | 16.70M |
| September 30, 2021 | 19.20M |
| June 30, 2021 | 15.70M |
| March 31, 2021 | 14.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Artivion, Inc. | 9.055M |
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 7.979M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |